IRCT20130313012810N16 IRCT 2023-10-31 Tasnim Comparative bioequivalence study of the Fexofenadine Hydrichloride 180 mg, tablet manufactured by Tasnim Company Comparative bioequivalence study of the Fexofenadine Hydrichloride 180 mg, tablet manufactured by Tasnim Company 2023-11-02 anticipated 24 Complete https://irct.ir/trial/73408 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other. Bioequivalence Bioequivalence study in healthy volunteers. Intervention group: This study examines the bioequivalence of Fexofenadine tablets produced by a domestic company with a foreign brand sample. We have only one intervention group and there is no control group. The intervention group, which includes healthy, fasting male volunteers, will receive a single dose, 180 mg tablet manufactured by the pharmaceutical company Tasnim and Allegra brand, in two 48-hour periods with an interval of one week, on the day of the study. And in 15 different time periods up to 48 hours after taking the medicine, blood samples will be taken from the volunteers in the amount of 3 ml each time, that is, a total of 45 ml within 48 hours. The training that will be given to the volunteers includes avoiding the consumption of drinks containing alcohol and xanthine and other interfering drugs in the prescription drug from 48 hours before the start of the study until the end of the study.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Industry license will be required